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ABSTRACT
Background: Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and
deep vein thrombosis (DVT), is the third most common acute cardiovascular disease and repre-
sents an important burden for patients and payers.
Objective: The aim was to estimate the cost-effectiveness of edoxaban, a non-VKA oral antic-
oagulant vs. warfarin, the currently most prescribed treatment for VTE in the UK.
Study design: A Markov model was built using data from the Hokusai-VTE randomised controlled
trial to estimate the lifetime costs and quality-adjusted life years (QALYs) in patients with VTE
treated with edoxaban or warfarin over a lifetime horizon, from the UK National Health Services
perspective. The model included VTE recurrences, VTE-related complications (post-thrombotic
syndrome and chronic thromboembolic pulmonary hypertension), and several types of bleeds
associated with anticoagulation treatment. Patients were treated during a period of 6 months
after the first VTE event, followed by flexible treatment duration (from 6 months to lifetime) after
recurrence, i.e., tertiary prevention.
Results: Edoxaban was found dominant vs. warfarin with 0.033 additional QALY and £55 less
costs. The reduction of patient management costs, specifically monitoring costs, outweighed the
higher drug costs. Edoxaban was dominant in all subgroups (index DVT only, all PE cases (PE with
or without DVT), PE without DVT and PE with DVT). Cost-savings ranged from £54 to £81 while
additional QALYs ranged from 0.031 to 0.046. Edoxaban was found dominant in 88.6% of cases
and cost-effective in additional 10.9% of cases considering a £20,000 threshold in the probabil-
istic sensitivity analysis.
Conclusion: Edoxaban may improve patients’ quality of life in a lifetime horizon without addi-
tional costs for the healthcare system due to lower bleeding risk and no monitoring cost
compared to warfarin.
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Introduction
Venous thromboembolism (VTE) is a potentially life-
threatening disease that includes deep vein thrombosis
(DVT) and pulmonary embolism (PE). VTE is charac-
terised by the presence of a thrombus in the deep
veins of the leg in cases of DVT, or in a pulmonary
vessel in cases of PE. The predominant symptoms of
DVT include pain, tenderness, and swelling of the
involved limb, while those of PE include dyspnoea,
tachypnoea, and pleuritic chest pain. Though DVT and
PE have different manifestations, they are considered to
be complementary manifestations of the same patho-
physiological process. It has been observed that about
66% of patients present with DVT only, whereas the
remaining present with PE [1]. VTE is a source of sig-
nificant economic burden in Europe. The total number
of symptomatic VTE events per year in Europe was
estimated to be over 684,000 cases of DVT, over
434,000 cases of PE, and over 543,000 VTE-related
deaths [2].
In the UK, pharmacotherapeutic treatment and pre-
vention of acute DVT and PE consists of the use of
different classes of anticoagulant medication. Current
standard of care involves initial treatment with a parent-
eral anticoagulant (such as subcutaneous low molecular
weight heparin (LMWH), unfractioned heparin (UFH), or
fondaparinux), followed by a vitamin K antagonist (VKA),
typically warfarin [3]. However, warfarin treatment has
many disadvantages, such as a narrow therapeutic
range, a need for careful dose adjustment, a need to
carefully monitor diet and concomitant medication, and
frequent monitoring of the international normalised ratio
(INR) [4]. Non-VKA oral anticoagulants (NOACs) such as
dabigatran, rivaroxaban, apixaban, and edoxaban have
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been recently recommended by the National Institute for
Health and Care Excellence (NICE) for VTE treatment[5].
NOACs are clinically non-inferior to VKAs, with fewer and
less serious side effects [6].
Edoxaban tosylate (Lixiana®) is a NOAC, which selec-
tively and reversibly inhibits coagulation factor Xa directly,
thus preventing the activation of prothrombin to thrombin.
After initial treatment with heparin, the recommended
dose for edoxaban is 60 mg once daily, with a dose reduc-
tion to 30 mg once daily for specific patient meeting pre-
defined characteristics depending on: renal function, low
body weight, and the use of P-gp inhibitors [7]. The
Hokusai-VTE trial was a phase III, event-driven, randomised,
double-blind, parallel-group, multi-centre, multi-national
non-inferiority study designed to evaluate the benefits
and risks of edoxaban compared to warfarin in reducing
the risk of symptomatic recurrent VTE in patients with
documented acute symptomatic DVT and/or PE. All
patients received an initial therapy with LMWH (enoxa-
parin) or UFH, followed by either edoxaban (60mg/30mg
dose reduced per day) or warfarin (dose adjusted to main-
tain INR between 2.0 to 3.0) in a double-dummy fashion.
The primary efficacy outcome was symptomatic recurrent
VTE, and the safety outcome was first major or clinically
relevant non major bleeds. The Hokusai-VTE trial included
8292 adults with VTE, edoxaban was reported to be non-
inferior for preventing recurrent VTE when compared to
warfarin, and treatment with edoxaban vs. warfarin
resulted in fewer bleeds [8].
The objective of this study was to develop a model
to estimate the cost-effectiveness of edoxaban vs.
warfarin in the treatment of and/or prevention of VTE
in a UK setting from an NHS perspective.
Materials and methods
Model description
A Markov model was developed to simulate the ther-
apeutic management of VTE patients, including the
potential adverse events of treatment and disease-
related complications. The model captured the impact
of VTE on quality of life, resource utilisation, and asso-
ciated costs over a lifetime horizon (50 years).
A total of eleven health states were defined to
describe the health outcomes and resource implications
of VTE management (Figure 1). Eight health states were
mutually exclusive: on treatment after an index VTE
(iVTE), off treatment, recurrent VTE (rVTE), on treatment
after an episode of rVTE, clinically relevant non-major
bleed (CRNMB), intracranial haemorrhage (ICH), non-ICH
major bleed (non-ICH MB), and death. Three health
states, describing the long-term consequences of VTE,
were defined as concomitant health states, i.e., a patient
could experience one or more of the three following
health states simultaneously with one of the eight health
states described previously: severe post-thrombotic syn-
drome (PTS), chronic thromboembolic pulmonary hyper-
tension (CTEPH), and disability following an ICH. The
chosen cycle length was one month, enabling patients
to transition between health states on a monthly basis.
The population included upon model entry was a
cohort of adult (≥ 18 years) patients that had initiated
Figure 1. Structure of the Markov model.
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treatment after an index VTE event (DVT and/or PE).
Upon model entry, each patient received either 6.5 days
of initial LMWH treatment followed by warfarin or
5 days of initial LMWH treatment followed by edoxaban
for a duration of 6 months. There was a possibility for
patients to experience an rVTE at the end of each cycle.
Patients could only experience adverse events (CRNMB,
non-ICH MB, and ICH) while on anticoagulant treat-
ment. Patients were assumed to discontinue treatment
following a major bleed, ICH, or non-ICH major bleeds.
After an rVTE, i.e., tertiary prevention of VTE, patients
who had both an index and recurrent PE (28% accord-
ing to the Hokusai-VTE trial) were assumed to initiate a
new anticoagulant strategy for a lifelong period, unless
the patient would experience an MB. The other patients
experiencing an rVTE were treated for 6 months. Death
rates were based on a combination of age-specific gen-
eral mortality rates and disease-specific mortality rates
for patients suffering from an rVTE, non-ICH MB, ICH,
disability following ICH or CTEPH.
The health outcomes included cumulative incidences
for rVTE, adverse events and complications, life years
and quality-adjusted life years (QALYs), average cumu-
lative costs per treatment (on treatment costs, adverse
events costs, total costs), the incremental cost-effective-
ness ratio (ICER), and the net monetary benefit (NMB).
The net monetary benefit was calculated according to
the following equation: NMB = ΔE.λ-ΔC, where λ
denotes the willingness-to-pay for a QALY gained, ΔE
the incremental QALYs, and ΔC the incremental costs.
The net monetary benefit represents the difference
between how much one would be willing to pay for
the additional QALYs gained by adopting the interven-
tion compared to the alternative intervention costs.
Finally, in accordance with NICE guidelines, an annual
discount rate of 3.5% was adopted for costs and out-
comes [9].
Transition probabilities
The baseline probabilities of VTE recurrence and bleeds
were derived from a post-hoc analysis of the Hokusai-
VTE clinical trial [8] (Table 1). Similarly, the odds ratios of
developing VTE recurrence and bleeds at baseline were
based on the same analyses of the Hokusai-VTE trial
data to estimate the time dependent probabilities. The
baseline probabilities and odds ratios were computed
on two time periods: for the first six months after
initiation of anticoagulant treatment, and for the fol-
lowing months. This was done to take into account the
time-dependent risks of developing an rVTE or a bleed-
ing event, as these events were more likely to occur in
the first six months.
As the Hokusai-VTE trial did not show a significant
difference in mortality rates following an ICH and non-
ICH MB for edoxaban vs. warfarin, the aggregated data,
i.e., the mortality rate for OACs combined, was mod-
elled. Whenever the model required data that could not
be retrieved from the Hokusai-VTE trial, transition prob-
abilities were derived from publications; these data
included the probability of developing CTEPH [10] and
PTS [11] after a VTE event, the probability of disability
following ICH [12], some disease-specific mortality rates
(due to a PE recurrence [13], the probability of dying
when disabled from ICH [14], and short-term [15] and
long-term mortality [16] from CTEPH), and the probabil-
ity of developing rVTE while off treatment [17] (Table 2).
The general mortality of the cohort depended on the
gender distribution and mean age across the time hor-
izon. To account for this gender and age distribution we
used UK life tables as source of input in our model [18].
Health utilities
A literature review was performed to obtain the utility
values associated with VTE (both DVT and PE), PTS and
CTEPH, treatment related (dis)utility values, and the
(dis)utility associated with potential adverse events.
The baseline utility levels for the general population
were obtained from the landmark national EQ-5D sur-
vey reported by Kind et al. [19]. These utility values
were used as a basis to estimate the utility values of
each health state in the present model.
The baseline utility values for DVT and PE esti-
mated by Cohen et al. [20] were weighted based on
the proportion of the cohort experiencing DVT and
Table 1. Efficacy and safety inputs of edoxaban vs. warfarin,
from the Hokusai-VTE clinical trial.
Parameter Base case value [DSA range]
Odds Ratio (OR) of edoxaban vs.
warfarin
First six months Following
months
VTE recurrence 0.83 [0.59–1.17]
*
0.82 [0.25–2.68]
*
CRNMB 0.78 [0.66–0.93] 0.89 [0.59–1.32]
*
Non-ICH MB 1.15 [0.75–1.75]
*
0.44 [0.13–0.42]
ICH 0.23 [0.07–0.81] 0.39 [0.08–2.02]
*
Baseline monthly probabilities
(event rate in warfarin arm)
First six months Following
months
VTE recurrence 1.8% [1.4–2.2%] 0.2%[0.0–0.4%]
CRNMB 1.7%[1.4–2.0%] 0.4%[0.2–0.6%]
Non-ICH MB 0.16%[0.07–
0.26%]
0.04%[0.00–
0.10%]
ICH 0.03%[0.00–
0.08%]
0.03%[0.00–
0.08%]
*Odds-ratios which were set to 1 in the scenario analysis. DSA:
Deterministic sensitivity analysis, OR: Odds-ratio, VTE: Venous
Thromboembolism, CRNMB: Clinically relevant non major bleeding, ICH:
Intracranial haemorrhage.
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PE, resulting in a utility value of 0.69 for iVTE, and an
estimated decrement of 14% for the first month fol-
lowing an rVTE [20]. A relative utility decrement of
1.37% was associated with warfarin treatment com-
pared to edoxaban treatment, as warfarin treatment is
known to lightly impact the quality of life due to the
frequent INR monitoring, and the numerous food and
drug interactions [21]. These discomforts are generally
not experienced by patients treated with edoxaban.
Utility decrements applied for CRNMB, non-ICH MB,
ICH, and disability post-ICH were 5.00%, 31.58%,
65.26%, and 65.26% respectively. Utility value decre-
ments of 13.68% and 30.00% were applied for every
case of PTS [22] and CTEPH [23] respectively, for all
subsequent cycles. For the few patients with both PTS
and CTEPH, the utility decrements were taken into
account multiplicatively.
Resource use and costs
The model included resource utilisation, drug prices,
and the costs of events and health states. All costs
were obtained from NHS reference costs 2015/16 [24]
(the latest available at the time of the study) unless
stated otherwise. The costs of the heparin lead-in, for
both edoxaban and warfarin, were solely applied to the
first cycle of treatment period following both the index
event and recurrence. The drug prices were obtained
Table 2. Inputs for the base case analysis and ranges of values used for the deterministic sensitivity analysis.
Parameter Base case value [DSA range]
Clinical parameters
Proportion of PE in index events [8] 40.1% [39.1–41.2%]
Proportion of PE with also DVT in index events [8] 44.1% [42.4–45.8%]
Proportion of PE among VTE recurrences [8] 56.5% [50.7–62.4%]
Probability of VTE recurrence while off treatment [10] 0.42% [0.36–0.49%]
Probability of developing CTEPH after a PE [10] 4.8% [2.3–9.6%]
Probability of developing PTS after a DVT [11] 2.7% [2.7–8.1%]
Probability to become disable after ICH event [12] 65% [56–75%]
Death after PE recurrence [13] 6.1% [3.0–30.8%]
Death after non-ICH MB [8] 6.1% [1.4–10.8%]
Death after ICH [8] 26.1% [8.1–44.0%]
Death after pulmonary endarterectomy (CTEPH) [15] 4.4% [2.6–6.2%]
Long-term monthly mortality post-ICH [14] 3.3% [1.4–3.3%]
Long-term monthly mortality post-CTEPH [16] 0.7% [0.6–0.7%]
Utility parameters
Utility PE [20] 0.67 [0.30–0.72]
Utility DVT [20] 0.71 [0.54–0.80]
Utility decrement with warfarin (vs. edoxaban) [21] 1.4% [0.0–1.9%]
Utility decrement due to CRNMB [22] 5% [0–10%]
Utility decrement due to Non-ICH MB [22] 32% [9–48%]
Utility decrement due to ICH [22] 65% [44–85%]
Utility decrement due to disability following ICH [22] 65% [44–85%]
Utility decrement due to CTEPH [23] 30% [26–34%]
Utility decrement due to PTS [22] 14% [0–31%]
Resource use & economic parameters
Anticoagulant treatment and heparin
Warfarin monthly costs (£) (eMIT) 1.22
Edoxaban monthly costs (first/subsequent) (£) 44.5/53.3
Heparin daily cost (incl. administration costs) (£) (BNF) 12.8 [7.9–15.5]
Days of heparin lead-in with warfarin/edoxaban 6.5 [5.0–8.5]/5.0 [5.0–7.5]
INR Monitoring while on warfarin
Cost INR visit First/Subsequent (£) [24] 87 [42–92]/26 [16–37]
INR visits for titration 4.0 [3.0–6.0]
Monthly INR visits (after 1st month) 1.0 [0.8–1.7]
VTE event costs
Costs per PE event (£) [24] 1,647 [1,238–3,668]
Cost per DVT event [24] 551 [654–1,086]
Costs due to Bleeding Complications (£)
Monthly costs for disabled ICH 524 [164–1,053]
Inpatient cost due to ICH [24] 3,012 [1,964–6,493]
Non-ICH MB (inpatient) [24] 2,940 [2,330–5,610]
CRNMB (inpatient + outpatient) [24] 384 [308–461]
CTEPH & PTS
Monthly PTS costs (First/Subsequent) (£) [24] 168 [167–173]/23 [23–24]
Cost of Pulmonary endarterectomy (£) [24] 7,824 [6,540–10,227]
% CTEPH patients undergoing endarterectomy [28] 50% [40–60%]
Monthly drug costs (£) (BNF) 1,348[1,078–1,617]
DSA: Deterministic sensitivity analysis, PE: Pulmonary embolism, DVT: Deep venous thrombosis, VTE: Venous thromboembolism, CTEPH: Chronic thromboem-
bolic pulmonary hypertension, PTS: Severe post-thrombotic syndrome, MB: Major bleeding, CRNMB: Clinically relevant non major bleeding, INR:
International normalised ratio, BNF: British National Formulary.
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from the British National Formulary (BNF) and from the
NHS Electronic Drug Tariff. Assuming equal use of all
heparins, the daily heparin cost was estimated as the
average cost of the four different heparin products
available in the UK and combined with the weighted
average of self-administration costs, and the cost of
administration by a professional. The administration
costs applied for a limited number of days and were
based on the assumption that 87% of patients will self-
administer LMWH (i.e., with no administration cost) [24].
The daily cost of warfarin was estimated to be £0.04
and the LMWH/heparin lead-in is 6.5 days for warfarin
and 5 days for edoxaban. Subsequently, the total cost
related to LMWH/heparin acquisition and administra-
tion was £64.10 for the edoxaban arm, and £83.33 for
the warfarin arm.
Since warfarin has a narrow therapeutic index,
repeated measurements of INR are required during
the course of treatment. The cost of treatment in the
warfarin arm, was £273.81 for the first cycle, 23.5 days
of treatment, (including INR monitoring and 6.5 day
concomitant heparin), and £26.73 for the following
cycles, 30 days of treatment, (including INR monitoring).
Patients on edoxaban received a 5 day heparin lead-in.
The daily cost of edoxaban was assumed to be £1.75.
Since INR monitoring is not required for NOACs like
edoxaban, the treatment costs in the edoxaban arm
included the drug acquisition costs for edoxaban and
heparin, and was estimated to be £108.62 during the
first cycle, 25 days of treatment with edoxaban (includ-
ing heparin), and £53.27 for the following cycles,
30 days of treatment with edoxaban.
The costs of VTE recurrence included hospitalisation
costs [25], costs related to diagnosis and treatment of
DVT (£551) and PE (£1,647, resulting in an average cost
of £1,236 per VTE recurrence. The cost of a major bleed
included the hospital admission costs. Accordingly, the
cost considered for ICH was £3,012, and that for non-
ICH MB was £2,940 [26]. Costs associated with CRNMB
were estimated to be £384 [26].
The PTS related costs included vascular surgery dur-
ing the first visit, and the costs related to the follow-up
visits. The cost for the first month was estimated to be
£168, corresponding to a first appointment for vascular
surgery, and the average cost for each of the following
months was estimated to be £23 per month, assuming
2 follow-up visits per year [27]. The costs related to
CTEPH included treatment costs, surgery and drug ther-
apy. Assuming that 50.3% of CTEPH patients required
pulmonary endarterectomy [28] with a unit cost of
£7,824, and follow-up costs of £1,348 per month, the
total average cost for CTEPH treatment was estimated
at £5,285 for the first month, and £1,348 for the
following months. The long-term impact of ICH result-
ing in disability was categorised as mild, moderate, and
severe for both the care centre costs and home care
costs. On average, the monthly costs for a disabled
patient with ICH were estimated to be £524 [12,29]. It
was assumed that there were no costs associated with
death and the off treatment health state.
Base case, sensitivity analyses, scenario analyses
and subgroup analyses
The base case analysis evaluated the costs and health
outcomes of edoxaban vs. warfarin for adults with an
index DVT and/or an index PE (index DVT ± PE) over a
lifetime horizon, assuming an initial treatment duration
of 6 months.
Sensitivity analyses were performed to evaluate the
impact of assumptions used in the model, and to assess
the variability surrounding model inputs. To identify
key drivers of the model, a univariate deterministic
sensitivity analysis was performed on all model para-
meters associated with uncertainty. In this analysis, one
parameter at a time was varied using lower and upper
bounds (Table 1). Those results are shown as a tornado
diagram. A multivariate probabilistic sensitivity analysis
was also performed to estimate the effect of overall
uncertainty in the evaluation through repeated sam-
pling of parameter values set to follow appropriate
statistical distributions. Two thousand simulations
were generated and the model was run for each set
of parameters, providing an estimate of the variability
of results. The results were presented by an incremental
cost-effectiveness plane and cost-effectiveness accept-
ability curves (CEACs).The following scenario analyses
were also investigated: reduced time horizon to 1 year
and 5 years and non-significant odds ratios set to 1.
Finally, the cost-effectiveness of edoxaban vs. war-
farin was analysed for four population subgroups
depending on the nature of the iVTE: patients with
index DVT but no index PE (Index DVT only), patients
with index PE with or without DVT (Index PE (± DVT)),
patients with index PE but no index DVT (Index PE
only), and patients with both index DVT and index PE
(Index PE + DVT).
Results
Base case
The results of the base case analysis are summarised in
Table 3. The cumulative incidences of rVTE, PTS, and
CTEPH were similar in both edoxaban and warfarin
arms. Yet, the cumulative incidence of adverse events
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Table 3. Model results for base-case and subgroups analysis.
1. Base case analysis, VTE population
2. Subgroup analyses
(a) Index DVT only (b) Index PE (± DVT) (c) Index PE – DVT (d) Index PE + DVT
Edoxaban Warfarin Edoxaban Warfarin Edoxaban Warfarin Edoxaban Warfarin Edoxaban Warfarin
Clinical outcomes (cumulative incidence over the time horizon)
VTE recurrence 105.53% 105.56% 124.42% 124.20% 83.77% 84.04% 86.15% 86.42% 78.54% 78.84%
CRNMB 13.85% 15.53% 13.51% 15.38% 14.63% 16.02% 16.41% 18.38% 11.41% 11.50%
Non-ICH MB 4.74% 4.62% 2.09% 2.15% 3.88% 3.50% 5.29% 4.62% 1.12% 1.32%
ICH MB 1.83% 2.09% 0.45% 0.74% 3.84% 4.07% 2.94% 3.25% 5.55% 5.66%
PTS 4.07% 4.07% 4.09% 4.08% 2.22% 2.22% 0.55% 0.55% 4.84% 4.85%
CTEPH 4.70% 4.70% 3.45% 3.45% 7.54% 7.55% 7.93% 7.94% 7.06% 7.06%
Specific Death 4.17% 4.29% 2.38% 2.51% 7.40% 7.51% 7.26% 7.40% 7.81% 7.87%
Health outcomes
Life years 16.523 16.494 16.678 16.645 16.169 16.143 16.141 16.109 16.186 16.170
QALYs 1.846 1.842 0.546 0.538 3.299 3.321 3.238 3.259 3.387 3.414
On treatment 10.703 10.677 12.347 12.322 8.696 8.642 8.732 8.674 8.623 8.571
Off treatment 0.040 0.040 0.046 0.046 0.034 0.034 0.034 0.034 0.032 0.032
Recurrent VTE 0.008 0.004 0.006 0.005 0.013 0.000 0.014 0.003 0.011 −0.006
Adverse Events −0.101 −0.099 −0.082 −0.081 −0.119 −0.117 −0.102 −0.101 −0.148 −0.146
Complications (PTS & CTEPH) 1.846 1.842 0.546 0.538 3.299 3.321 3.238 3.259 3.387 3.414
Total QALYs 12.497 12.464 12.862 12.831 11.923 11.880 11.917 11.870 11.905 11.865
Costs
Treatment costs (excluding INR monitoring) £392 £90 £392 £90 £392 £90 £391 £90 £394 £90
INR monitoring £0 £323 £0 £323 £0 £323 £0 £323 £0 £324
Recurrent VTE (acute & treatment) £2,045 £2,049 £1,252 £1,250 £3,063 £3,091 £3,101 £3,128 £3,016 £3,048
CRNMB £71 £77 £39 £46 £131 £137 £123 £131 £147 £149
Non ICH MB £92 £89 £51 £53 £82 £70 £109 £89 £27 £33
ICH (acute and long term costs) £98 £124 £33 £62 £197 £220 £150 £180 £286 £295
Complications (PTS & CTEPH) £4,439 £4,439 £2,431 £2,427 £7,985 £7,994 £8,168 £8,177 £7,785 £7,797
Total costs £7,136 £7,191 £4,198 £4,252 £11,850 £11,925 £12,042 £12,118 £11,656 £11,736
Cost-effectiveness analysis
Incremental QALYs 0.033 0.031 0.043 0.046 0.046
Incremental costs -£55 -£54 -£74 -£76 -£81
Cost per QALY gained (ICER) Dominant Dominant Dominant Dominant Dominant
Net Monetary Benefit £717 £680 £939 £1,005 £880
PE: Pulmonary embolism, DVT: Deep venous thrombosis, VTE: Venous thromboembolism, CTEPH: Chronic thromboembolic pulmonary hypertension, PTS: Severe post-thrombotic syndrome, MB: Major bleeding, CRNMB:
Clinically relevant non major bleeding, INR: International normalised ratio, ICER: Incremental cost-effectiveness ratio.
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(CRNMB, non-ICH MB and ICH MB) was lower in the
edoxaban arm. As a consequence of fewer MBs in the
edoxaban arm, mortality was also lower. These results
translated into an improvement of health outcomes,
with 0.029 incremental life years and 0.033 incremental
QALYs gained, compared to warfarin. Treatment-related
costs for people treated with edoxaban were higher
while costs related to adverse events were lower due
to fewer bleeds experienced by patients treated with
edoxaban. The cumulative benefits related to edoxaban
vs. warfarin (0.033 QALY) were associated with lower
total costs for edoxaban (-£55 versus warfarin) resulting
in edoxaban being dominant when compared to war-
farin. Assuming a threshold of £20,000 per QALY, the
corresponding NMB was £717 (Confidence interval:
[£398; £960]).
Sensitivity analyses
Deterministic sensitivity analysis
Deterministic sensitivity analyses were conducted on the
NMB, and the 10 main drivers of the analyses are illu-
strated in the tornado diagram (Figure 2). The main driver
was the probability of occurrence of ICH with a NMB
ranging from £487 to £947. The other important drivers
of the analysis were the probability of occurrence of rVTE
and non-ICH MB between edoxaban and warfarin, and
inputs related to the INR monitoring in the warfarin arm
(number and cost of the INR visits). When the assumed
disutility of 1.4% associated with the use of warfarin to
reflect the added burden of monitoring visits on the
patient’s quality of life was removed, the NMB dropped
to £694, against £717 in the base case. In all cases
explored in the deterministic sensitivity analyses,
edoxaban remained cost effective compared to warfarin
when considering a £20,000 willingness-to-pay per QALY.
Probabilistic sensitivity analysis
Over the 2,000 simulations of the probabilistic sensitiv-
ity analysis, edoxaban was dominant (less costs and
more QALYs) in 88.6% of cases (Figure 3(a)). Moreover,
when considering a £20,000 willingness-to-pay per
QALY, edoxaban was cost-effective vs. warfarin in
99.5% of cases (Figure 3(b)).
Scenario analyses
When the non-significant odds ratio was set to 1, edox-
aban remained dominant compared to warfarin, but
with a smaller difference: £41 of savings and 0.03 addi-
tional QALYs with edoxaban compared to warfarin.
With a reduced time horizon, edoxaban was still found
to be dominant, with £42 and 0.007 additional QALYs
and £56 and 0.012 additional QALYs with a 1-year and
5-year time horizon respectively.
Subgroup analyses
The results of the subgroup analyses (Table 3) were similar
to the results obtained in the base case analysis. In the
four subgroups, the incidence of rVTE was similar in both
edoxaban and warfarin arms. Edoxaban was also asso-
ciated with fewer adverse events, except for non-ICH
MBs in the PE without DVT subgroup where there were
fewer events in the warfarin arm (3.93% vs. 3.42%)
although these rates were associated with high uncer-
tainty (OR [95%CI]: 1.74 [0.82–3.70]) due to a small num-
ber of events observed in each arm of the Hokusai-VTE
Figure 2. Deterministic sensitivity analysis of the cost effectiveness of edoxaban vs. warfarin (the 10 most impactful parameters are
shown).
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Figure 3. Incremental cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b) of edoxaban vs. warfarin (n = 2,000
simulations).
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trial. The costs saved with edoxaban were higher in the
three subgroups including patients with index PE than in
the base case (-£74 in the PE with or without DVT sub-
group, -£76 in the subgroup with index PE without DVT
and -£81 for patients with both index PE and index DVT)
due to lower cost differences attributed to adverse events,
while incremental QALYs were above 0.04. Results were
slightly less in favour of edoxaban in the index DVT only
subgroup with more VTE recurrences in the edoxaban
arm than in the warfarin arm, compensated by fewer
bleeds. The incremental QALYs and costs were 0.031
and -£54 in the latter subgroup.
Discussion
The current analyses evaluated the cost-effectiveness of
edoxaban in comparison to warfarin for the treatment of
VTE for the UK setting from an NHS perspective.
Edoxaban was consistently associated with greater
QALYs and lower costs than warfarin and is therefore
dominant when compared to warfarin, although the cost
difference was not substantial. Subgroup analyses con-
firm the results to be consistent with the general VTE
population with edoxaban being dominant (lower costs
and higher QALYs gained) for all the subgroup analyses.
Sensitivity analyses revealed that the findings of the base
case analysis were robust despite variations in the inputs.
The main driver of the model is the probability of an ICH
occurrence and the incidence of ICH is likely to be higher
in patients not included in clinical trials. The scenario
analyses with non-significant OR set to 1 confirmed the
robustness of the base case results as well as the scenar-
ios with a shorter time horizon.
Another cost-effectiveness study of edoxaban for the
treatment of VTE in adults in comparison to warfarin
was performed in the USA. The model was developed
using patient-level data from the Hokusai-VTE trial, with
clinical events costs from a real-world database.
Edoxaban was found to be a cost-effective alternative
to warfarin in VTE patients in the USA with an ICER of
$22,057 per QALY [30]. The high ICER in the US study
compared to our study partly resided in a greater dif-
ference in the daily drug costs between edoxaban and
warfarin ($9.24 vs. $0.36 in the US, against £1.75 vs.
£0.04 in the UK).
Other NOACs have been approved in the UK for the
treatment and secondary prevention of venous throm-
boembolism, namely apixaban, dabigatran and rivarox-
aban. We did not include these molecules in the
analysis for two main reasons. First, the standard of
care in the UK remains treatment with a VKA such as
warfarin, thus it is the principal comparator for edoxa-
ban. Second, evidence regarding potential differences
in efficacy and safety between the NOACs is scarce, as
there is still no direct comparison available. Several
indirect treatment comparisons have been performed
[31–33], indicating similar results overall. Apixaban was
found to have a comparative advantage over the other
NOACs in terms of bleed occurrences, although there
has been high uncertainty around these results, the
clinical trials of the NOACs being substantially different
in their designs. However, as the other NOACs are likely
to become the standard of care, further investigations
comparing all the NOACs together should be per-
formed in the future.
The current model has a comprehensive structure
which includes eleven different health states, encom-
passing all the relevant (adverse) events and complica-
tions that a patient with VTE treated with oral
anticoagulants might encounter. The life-time horizon
assures the inclusion of both the short term as well as
the long term consequences of VTE, such as PTS and
CTEPH. Our model is similar to previously validated,
published models in this therapeutic area [34], while
allowing greater flexibility in terms of allowing for var-
ious treatment durations, and analysis of different sub-
groups. The model takes into account the current
recommendations by treating VTE recurrence longer
than the first event (6 months for first event in the
base case, from 6 months to long term treatment
after a VTE recurrence depending on the type of recur-
rence). The model accounts for time-varying event rates
(first 6 months of treatment vs. following months).
Therefore, the model allows for a more accurate pre-
diction of cumulative events as the (adverse) event
rates and complications related to VTE are more likely
to occur during the first six months. Finally, the model
relies on robust clinical data mainly stemming from a
clinical trial designed to reflect clinical practice.
However, the model has also several limitations.
Indeed, the VTE patient population is heterogeneous,
resulting in a broad spectrum of treatment strategies
for the related subgroups. To keep the model simple
and transparent, a number of assumptions were made.
First, all patients were assumed to be treated for the
same initial treatment period (irrespective of the VTE
type; DVT or PE). The model did not distinguish
between provoked and unprovoked VTE as the
HOKUSAI study was able to enrol both types of
patients. Patients with provoked VTE are treated for a
shorter period of time since they have a lower risk of
VTE recurrence.
Second, all patients experiencing a major bleed were
assumed to discontinue anticoagulation therapy until
the potential for next VTE recurrence appears. Stopping
anticoagulant treatment is in line with clinical practice:
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the priority being to reverse bleeding, so continued
anticoagulation would be inappropriate. We accept
that some patients would recommence anticoagulation
after a major bleed, particularly in the first 2 months
following the diagnosis of VTE. These patients would be
at higher risk of a bleeding recurrence. However, it is
not clear what would happen after a VTE recurrence
following a previous major bleed. This remains a rela-
tively rare situation.
Third, DVT andPEweremodelledwithin the samehealth
state. Although some other models considered separate
states for PE and DVT, this approach seemed appropriate
due to the lack of detailed data regarding the long-term
sequence of recurrences for PE and DVT. The model takes
the proportion of DVT and PE occurrences into account in
the weighted average of related costs and probabilities of
the disease related complications, PTS and CTEPH.
Finally, there were uncertainties regarding some
inputs used in the model. For instance, the true costs
of INR monitoring are currently highly debated in the
literature [35]. Conservative estimates were taken into
account in the base case, while uncertainty around
these costs was considered in the sensitivity analyses.
The sensitivity analyses showed that variations regard-
ing these parameters were not likely to impact the
conclusion of this analysis.
For future investigation it will be of huge interest to
perform a cost-effectiveness analysis including all the
NOACs and using real-world data instead of clinical trial
data to feed the model.
Conclusion
Based on data from the Hokusai-VTE trial and relevant
publications used to populate the model, this analysis
suggests that edoxaban represents a valuable alterna-
tive compared to warfarin for the treatment of patients
with VTE in the UK.
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